3 Reasons SUPN is Risky and 1 Stock to Buy Instead

Supernus Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.1%. The stock now trades at $53.23, marking a 17.1% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.